Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 5, 2015, Pages 508-512

  Freund, K Bailey ^a   Engelbert, Michael ^a   Fine, Howard F ^b  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b NJ Retina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ANGIOGRAPHY; ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GEOGRAPHIC ATROPHY; HUMAN; INTENSIVE CARE; LONG TERM CARE; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MULTIMODAL IMAGING; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; PERSONALIZED MEDICINE; PHOTORECEPTOR; PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RETINA DETACHMENT; ANTAGONISTS AND INHIBITORS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; VISUAL ACUITY; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; PRECISION MEDICINE; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84930442296     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150521-01     Document Type: Article

References (11)

1. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-2299.
2. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424-1431.
3. Stone TW, ed. ASRS 2014 Preferences and Trends Membership Survey. Chicago, IL; American Society of Retina Specialists; 2014.
4. Grunwald JE, Daniel E, Huang J. et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trial. Ophthalmology. 2014;121(1):150-161.
5. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2- year findings of the IVAN randomized controlled trial. Lancet. 2013;382:1258-1267.
6. Sadda SR. Development of atrophy in neovascular AMD treated with anti-VEGF therapy: Results of the HARBOR Study. AAO Retina Subspecialty Day 2014, Chicago, IL.
7. Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol. 1998;126(1):59-69.
8. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333-1349.
9. Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina. 2015;35(2):176-186.
10. Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014;158(4):769-779.
11. Marcela M, Boddu S, Chen C, et al. Correlation between neovascular lesion type and clinical characteristics of non-neovascular fellow eyes in patients with unilateral neovascular age-related macular degeneration. Retina. 2015;35(5):966-974.